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Abstract A growing number of reports suggest a connection between hepatitis C
virus (HCV) infection and type 2 diabetes (T2D). However, the association of HCV
infection with diabetes-related complications has not yet been clariﬁed. The aim
of this study was to determine the prevalence of HCV infection in T2D-patients
in Kuwait which has a high incidence of type 2 diabetes, and to investigate the
association between HCV viremia and diabetes-related complications. A total of
438 patients with T2D (325 Kuwaitis and 113 Egyptians), and 440 control subjects,
were enrolled for this study. HCV infection was assessed by testing for serum HCV-
speciﬁc antibodies, and by detection of HCV RNA. HCV viral load and hemoglobin A1c
(HbA1c) levels were assessed in patients with and without diabetes complications.
Thirty one (7%) out of 438 T2D-patients had evidence of HCV infection compared
to 4 (1%) out of 440 control adults (p < 0.0001). The prevalence of HCV infection in
Kuwaiti and Egyptian T2D-patients was 3% and 18%, respectively. Most of the HCV
sequences detected in T2D patients and control subjects were of genotype 4. The
HbA1c levels in T2D-patients with HCV viremia were signiﬁcantly higher than those
in HCV-negative patients. HCV viremia, female sex, age, family history of diabetes
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ntroduction
iabetes mellitus is a major public health problem
n Kuwait and is one of the fastest growing diseases
round the world. It is estimated that 15—21% of the
uwaiti adult population have type 2 diabetes (T2D)
1,2]. The incidence of diabetes in Kuwait is very
igh compared with neighbouring Arab countries,
nd it may be the result of the rapid economic and
ocial development which took place after the oil
oom in Kuwait. Family history of diabetes, obesity,
iets high in calories and lack of exercise have all
een identiﬁed as risk factors for developing T2D
n Kuwaiti population [1,2], suggesting that T2D in
uwait is probably caused by a complex interaction
f genetic and environmental factors as described
lsewhere [3,4].
An increased prevalence of glucose abnormal-
ties and diabetes mellitus among patients with
hronic hepatitis C virus (HCV) infection has
een reported in several studies [5—10], includ-
ng those done in Kuwait [11—13]. The connection
etween diabetes and HCV infection has also been
emonstrated in anti-HCV seroprevalence studies in
ohorts with diabetes. In a selected group of T2D-
atients with abnormal serum aminotransferases,
8% of black and 12% of white patients had evi-
ence of HCV infection [14]. A higher prevalence
f HCV infection has also been reported in Spain in
iabetic patients (11.5%) in comparison with blood
onors (2.5%) [15]. Moreover, 4.2% of patients from
diabetes clinic in North America, were found to
e positive for anti-HCV antibodies, compared with
.6% in the control patients [7].
In spite of the growing number of reports showing
link between HCV infection and diabetes mellitus,
he association of HCV infection with diabetes-
elated complications has not yet been clariﬁed. In
he current study, the prevalence of HCV infection
n Kuwaiti population with T2D was ﬁrst compared
o that in Egyptian immigrants, owing to the fact
hat Kuwaiti nationals comprised only 32% of the
opulation, and Egyptian immigrants comprised the
ajor part of Arabs living in Kuwait [16]. The
l
1
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nt risk factors for diabetes complications. The results
Kuwait have higher prevalence of HCV infection than
ia is associated with diabetes-related complications.
ziz University for Health Sciences. Published by Elsevier
ssociation of HCV infection with diabetes-related
omplications was then investigated.
ethods
ollection of blood samples
bout 20% of the adult Kuwaiti population is
stimated to have T2D [1,2]. The Kuwaiti adult pop-
lation size is estimated to be 686,774 [16]. The
ample size obtained by power calculation for sim-
le random sample is 322 T2D-patients assuming
0% prevalence of HCV infection, 95% conﬁdence
nterval and 0.05 as maximum accepted error. The
nclusion criteria for this study were adult patients
ith documented T2D. The exclusion criteria were
atients with other types of diabetes, diabetic
atients with history of viral hepatitis, liver cir-
hosis, or hepatocellular carcinoma. Venous whole
lood samples in sterile 5ml plain tubes were col-
ected from 438 T2D patients (325 Kuwaitis and
13 Egyptians; 278 males and 160 females; median
ge, 47 years), recruited from Amiri Hospital,
ubarak Al-Kabeer Hospital, and Kuwait Diabetes
ociety. The HCV status was not known for any
f the recruited diabetic patients at the time of
atient visit and blood collection. Each patient
ncluded in this study was receiving one or com-
ined medications according to his condition. The
reatment included hypoglycemic drugs, antihyper-
ensive drugs, and anti-cholesterol drugs. The last
emoglobin A1c (HbA1c) level and the presence of
iabetes-related complications such as hyperten-
ion, hyperlipidemia, cardiovascular, renal, ocular
r neurological disease, were recorded for all
atients in addition to their demographic data
ncluding nationality, gender, age, body mass index
BMI), and the presence of family history of dia-
etes.
The same type of blood samples was also col-ected from 440 control subjects (308 Kuwaitis and
32 Egyptians; 255 males and 185 females; median
ge, 47 years) recruited from the same hospitals.
l
5
o
a
H
T
s
A
n
t
S
T
m
w
g
f
(
a
b
e
c
r
p
d
R
H
T
T
t
2
p
t
p
E
t
(
s
t
p
p
w
(202
These control subjects included patients who came
to the outpatient clinic of the hospital for follow-up
after having received treatment for acute respira-
tory illness, acute gastroenteritis, or urinary tract
infection. They had no chronic or malignant dis-
eases. The HCV status was not known for any of the
recruited control subjects. All the blood samples
were collected after obtaining written informed
consent from patients and controls. The ethical per-
mission on this research study was granted by the
Ethical Decision Committee of the Research Admin-
istration, Faculty of Medicine, Kuwait University,
and by the Standing Committee for Coordination of
Health and Medical Research, Ministry of Health of
Kuwait.
Detection of HCV-speciﬁc antibodies by an
immunoassay (ELISA)
To determine the presence of HCV-speciﬁc anti-
bodies in serum samples, the INNOTEST HCV Ab IV
ELISA Kit (Innogenetics, Ghent, Belgium) was used
according to the manufacturer’s instructions. The
optical density (OD) values were determined at
450 nm by an ELISA reader, the Labsystems Multi
Skan MS (Labsystems, Helsinki, Finland).
Nested-RT-PCR for the detection of HCV
infection
Total RNA was extracted from the serum of patients
and controls using the Qiagen QIAamp viral RNA
mini kit (Qiagen Sciences, Maryland, USA). Eluted
RNA was used for nested RT-PCR assay. The presence
of HCV RNA from clinical specimens positive for
anti-HCV antibodies was detected by nested RT-PCR
assay as previously described [17]. The ampliﬁed
PCR product was separated on 2% agarose gel elec-
trophoresis, and visualized using UVP BioImaging
System (UVP Ltd., Cambridge, UK). Image process-
ing and analyses of DNA bands were performed using
LabworksTM Image Acquisition and Analysis Soft-
ware (UVP Ltd.).
Quantiﬁcation of HCV RNA detected in
T2D-patients and controls
Real-time reverse transcription-PCR for the quan-
tiﬁcation of HCV RNA was carried out on LightCycler
2.0 instrument, as described previously [18]. For
absolute quantiﬁcation, the pGEM-T Easy vector
(Promega, Madison, USA) containing the 217-bp
insert fragment of the 5′ untranslated region (UTR)
of HCV genotype 4, was used at different con-
centrations to generate the standard curve. The
H
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inear range of the assay was from 5× 103 to
× 1010 copies/ml. Patients with an HCV viral load
f more than 2million copies/ml were considered
s having high viral load.
CV genotyping
he genotype of HCV RNA detected in clinical
pecimens was determined using the Versant HCV
mpliﬁcation 2.0 LiPA assay (Siemens Medical Diag-
ostics Solutions, Tarrytown, NY, USA) according to
he manufacturer’s instructions.
tatistical analysis
he continuous variables were expressed as
edian, and the two-tailed Mann—Whitney U-test
as used to assess the difference between two
roups. The 2× 2 contingency table was performed
or the categorical variables using the chi square
2)-test and Fischer’s exact test, as appropri-
te. Multivariate logistic regression analysis with
ackward stepwise selection method was used to
valuate the predictive baseline variables that
ould be associated with the presence of diabetes-
elated complications. All statistical analyses were
erformed using SPSS software version 17.0 for Win-
ows (SPSS, Chicago, IL, USA).
esults
epatitis C prevalence in diabetic patients
he overall seroprevalence of HCV antibodies in
2D-patients (7%) was signiﬁcantly higher than
hat in control subjects (1%) (OR = 8.3; 95% CI,
.8—27.9; p < 0.0001). Kuwaiti and Egyptian T2D-
atients have higher prevalence of HCV infection
han that of their corresponding controls (Kuwaiti
atients: p = 0.001; Egyptian patients: p < 0.0001).
gyptian T2D-patients were 6 times more likely
o have HCV infection than Kuwaiti T2D-patients
OR = 6.1; 95% CI, 2.7—14.7, p < 0.0001, Table 1).
In the group of control subjects, 3 out of 4 HCV
eropositive Egyptian subjects were HCV RNA posi-
ive, while in the group of T2D-patients, 24 out of 31
atients had evidence of HCV viremia (Table 1). The
revalence of HCV viremia in T2D-patients (5.5%)
as signiﬁcantly higher than that in control subjects
0.7%) (OR = 8.4; 95% CI, 2.5—44.05; p < 0.0001).
CV genotype 1 was detected in only two Kuwaiti
atients, and all remaining HCV-infected patients
nd controls had HCV genotype 4 infection. The
istribution of gender, family history of diabetes,
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Table 1 HCV infection in T2D-patients and controls.
Subject group HCV antibodies,
n (%)
HCV RNA,
n (%)
T2D-patients
Kuwaitis (n = 325) 11 (3%) 8 (2.5%)
Egyptians (n = 113) 20 (18%) 16 (14%)
Males (n = 278) 21 (7.5%) 16 (6%)
Females (n = 160) 10 (6%) 8 (5%)
Control subjects
Kuwaitis (n = 308) 0 (0%) 0 (0%)
Egyptians (n = 132) 4 (3%) 3 (2%)
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ge and BMI in T2D-patients with HCV viremia was
ot statistically different from that in T2D-patients
ith no evidence of HCV infection. Furthermore,
he demographic data of Kuwaiti patients with
CV viremia were comparable to those of Egyptian
atients (Table 2).
epatitis C and diabetes-related
omplications
o investigate whether HCV viremia has a role in
he occurrence or precipitation of diabetes-related
omplications such as hypertension, hyperlipi-
emia, cardiovascular, renal, ocular or neurological
isease, the HbA1c levels and the proportion of
2D-patients with diabetes-related complications
ere determined in patients with and without
CV viremia. The HbA1c levels in T2D-patients
ith HCV viremia (median = 8.5%; range: 4.7—10.8)
ere signiﬁcantly higher than those in HCV-
egative patients (median = 6.7%; range: 4.5—10.8;
= 0.015). Diabetes-related complications were
eported in 23 (96%) out of 24 T2D-patients
ith HCV viremia, and in 304 (73%) out of 414
2D-patients with no evidence of HCV infection
p = 0.014). This association remained highly sig-
iﬁcant when the results were adjusted for other
otential predictive variables for diabetes com-
lications (Table 3). Female sex, age and family
istory of diabetes were also found to be indepen-
ent risk factors for diabetes complications.
The association between HCV viremia and
iabetes complications may be the result of a signif-
cant difference in the viral load between patients
ith and without diabetes complications. To test
his hypothesis, HCV viral load was measured in all
2D-patients with HCV viremia. The median HCV
NA concentration in patients with diabetes com-
lications was 4.1× 106 copies/ml (range: 6.3× 104
o 3.5× 107 copies/ml), and that obtained in the
ingle patient with no diabetes complications was T
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Table 3 Independent risk factors for diabetes-
related complications.
OR (95% CI) p-Value
Gender
(male/female)
0.19 (0.09—0.38) <0.0001
Age 1.07 (1.04—1.1) <0.0001
Family history of
diabetes (yes/no)
42.03 (15.83—111.63) <0.0001
HCV viremia
(yes/no)
23.65 (2.36—236.64) 0.007
Multivariate logistic regression model with backward step-
wise selection method. The variables in each model included
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fnationality, gender, age, body mass index, family history of
diabetes, HbA1c levels and HCV viremia. OR, odds ratio; CI,
conﬁdence intervals.
5.5× 105 copies/ml (p = 0.28). High viral load was
only found in 12 (52%) out of 23 patients with dia-
betes complications.
Discussion
The high prevalence of HCV infection obtained in
Kuwaiti T2D-patients (3%) compared to that in con-
trol subjects (0%), and to that previously reported
in Kuwaiti blood donors (0.8%) [19], support pre-
vious studies that have noted a 2- to 10-fold
increase in the seroprevalence of HCV infection
in diabetic patients [7,14,20]. The higher preva-
lence of HCV infection in T2D patients may be
due to increased exposure to medical interventions
leading to an additional risk for acquiring HCV infec-
tion. However, this study cannot exclude the role
of HCV infection in the development of diabetes,
since results from previous studies have shown that
patients with chronic HCV genotype 4 infection
have an increased risk to develop glucose abnor-
malities [11—13].
The higher HCV seroprevalence in Egyptian T2D-
patients compared to Kuwaiti patients could not be
explained by a difference in the demographic data
between the two populations. Even though the HCV
seroprevalence in Egyptian patients with T2D was
higher than that in control subjects (18% vs 3%), it
was comparable to that described in the general
Egyptian population [21]. Age, sex, marriage, rural
residence, injections for bilharziasis, urography and
blood transfusions have all been reported as risk
factors for HCV infection in Egypt [21—23].
The results from this study have shown that
HbA1c levels were not associated with diabetes
complications. However, a single measurement of
HbA1c levels can lead to an underestimation of
the importance of HbA1c as a risk factor, as
described earlier [24]. The updated mean of HbA1c
C
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sing several values has been found to be bet-
er and is widely used [24—26]. Contrary to HbA1c
esults, HCV viremia was associated with increased
ccurrence of diabetes-related complications. Fur-
hermore, the HCV viral load in 52% of patients with
iabetes-related complications was high. These
esults should be conﬁrmed with larger number of
CV-infected patients with and without diabetes-
elated complications.
Interestingly, the results showed that women
ave 5 times more risk to develop diabetes-
elated complications than men. The difference
n patients’ gender with regard to the clinical
resentation and clinical features of diabetes-
elated complications, has been well documented,
ith more signiﬁcant impact on women than
en [27—31]. The proportion of worldwide deaths
ttributable to diabetes mellitus is estimated to be
igher in females than in males, with 1.5million and
.4million deaths respectively [32].
Most of the HCV RNA detected in T2D-patients
ere of genotype 4. HCV genotype 4 is the predom-
nant genotype in the Middle East including Kuwait
33,34]. Patients with genotype 4 have greater
brosis progression rates, and are signiﬁcantly more
ikely to have cirrhosis than are patients with dif-
erent HCV genotype infections [35]. In addition,
atients infected with HCV genotype 4 are less
ikely to respond to therapy than those infected
ith genotypes 2 and 3 [36,37]. A sustained viro-
ogic response rate of 68% to combination therapy
as been reported in Kuwait in non-cirrhotic HCV-
atients [38]. The overall prevalence of T2D in HCV
enotype 4 infection in Kuwait was around 40%
12,13], which is not different from that reported
n previous studies conducted in North America
nd Europe where different HCV genotypes are
irculating [6,7,39]. The results of this indicate
o difference between HCV genotypes detected in
2D patients and those detected in HCV-infected
ontrol subjects. In addition, there was no signiﬁ-
ant difference in the distribution of HCV genotype
etween patients with diabetes-related complica-
ions and those with no evidence of diabetes com-
lications. Consequently, HCV genotype 4 is proba-
ly not associated with increased risk for diabetes-
elated complications. These observations are in
ine with results of an earlier study showing that
CV genotype 4 is not associated with increased risk
or diabetes compared to other genotypes [11].onclusion
higher prevalence of HCV viremia in patients
ith T2D compared to that in non-diabetic
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[epatitis C virus infection in a population with high
ubjects, was found in this study. Since HCV viremia
as associated with increased occurrence of dia-
etes complications, and since there is a growing
ody of evidence supporting the link between dia-
etes mellitus and the development of liver cancer
n HCV-patients [40—42], national health promo-
ion campaigns and prevention programs should be
argeted to T2D-patients who are at high risk to
ontract a blood-borne infection like HCV.
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